Conflicting Post-Bilski Cases: Classen And CyberSource

Law360, New York (September 15, 2011, 1:48 PM EDT) -- What methods cannot be patented, even if they are novel and useful? A deeply divided Federal Circuit panel struggled with that question in Classen Immunotherapies Inc. v. Biogen Idec, No. 2006-1634 (Aug. 31, 2011). Classen reveals that the Federal Circuit remains split on method patents after the U.S. Supreme Court’s decision in Bilski v. Kappos, 130 S. Ct. 3218 (2010).

§ 101 of the Patent Act provides that a patent can be granted on a new and useful process, machine, manufacture or composition of matter. The...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.